NEJM: Need to be treated with thrombosis before thrombosis in patients with large vascular blocking acute ischemic stroke

For patients with acute ischemic stroke, the benefits and risks of intravenous injection of atepase before an intravascular thrombosis operation remain uncertainresearchers recently assessed the efficacy of intravenous injection seisses in patients with acute ischemic stroke before blood vessel thrombosisPatients with acute ischemic stroke with pre-circulating large vascular clottedness were randomly treated only for intravascular thrombosis (thrombosis group) or given intravenous artepase within 4.5 hours of the onset of symptoms, followed by an intravascular thrombosis, with a dose of 0.9 mg per kilogram of body weight (combined treatment group)The main endpoint of the study was a 90-day-revised difference in the rankin score, with secondary results including death and vascular reflux656 patients participated in the study, of which 327 received only thrombosis and 329 patients received combined treatmentPure intravascular thrombosis in the secondary outcome is not inferior to intravenous atepase combined intravascular thrombosis group (adjusted common advantage ratio: 1.07), but the combination of patients prior to thrombosis successful re-pass (2.4% vs 7.0%) and the overall re-pass rate is higher (79.4% vs84.5%)The 90-day mortality rate was 17.7% in the pure thrombosis group and 18.8% in the combined treatment groupstudies, there was no significant difference in the effect of prognosis on patients with large vascular lysate acute ischemic stroke, the effect of simple thrombosis and intravenous atepase combined thrombosis on the prognosis of patients